NasdaqCM - Nasdaq Real Time Price ? USD AVITA Medical, Inc. (RCEL) Follow Compare 11.40 +0.23 (+2.06%) At close: 4:00 PM EST 11.69 +0.29 (+2.54%) After hours: 6:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations AVITA Medical to Announce Third Quarter 2024 Financial Results VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on Thursday, November 7, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 8, 2024, a GlobeNewswire ? 26 days ago AVHHL RCEL +2.06% AVITA Medical (NASDAQ:RCEL) shareholders have endured a 74% loss from investing in the stock five years ago While not a mind-blowing move, it is good to see that the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has gained... Simply Wall St. ? 26 days ago AVHHL RCEL +2.06% Top High Growth Tech Stocks To Watch In September 2024 The market is up 1.6% over the last week, with the Information Technology sector up 4.2%. In the last year, the market has climbed 22%, and earnings are forecast to grow by 15% annually. In this thriving environment, identifying high-growth tech stocks that align with these optimistic trends can be crucial for investors looking to capitalize on future opportunities. Simply Wall St. ? last month TBLA TBLAW AVHHL AVITA Medical to Present at 2024 Cantor Global Healthcare Conference VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O’Toole, Chief Financial Officer, will present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. Eastern Time. A live webcast of the presentation will be accessible under the Events & Presentations GlobeNewswire ? last month AVHHL RCEL +2.06% AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street Capital Markets’ 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024. Jim Corbett, Chief Executive Officer, will host one-on-one meetings with institutional investors throughout GlobeNewswire ? last month AVHHL RCEL +2.06% AVITA Medical Inc (NASDAQ:RCEL) A Bull Case Theory We came across a bullish thesis on AVITA Medical Inc (RCEL) on ValueInvestorsClub by FT42. In this article we will summarize the bulls’ thesis on RCEL. AVITA Medical shares were trading at $9.88 when this thesis was published, vs. closing price of $9.11 on Aug 29. AVITA Medical is at the forefront of regenerative medicine, […] Insider Monkey ? 2 months ago RCEL +2.06% AVITA Medical Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags AVITA Medical ( NASDAQ:RCEL ) Second Quarter 2024 Results Key Financial Results Revenue: US$15.2m (up 29% from 2Q... Simply Wall St. ? 2 months ago AVHHL RCEL +2.06% Is AVITA Medical, Inc. (RCEL) Among the Best Cosmetic Surgery and Aesthetics Stocks to Buy Now? We recently compiled a list of the 10 Best Cosmetic Surgery and Aesthetics Stocks To Buy. In this article, we are going to take a look at where AVITA Medical, Inc. (NASDAQ:RCEL) stands against the other cosmetic surgery and aesthetics stocks. While imperfections are inherent to being human, aesthetic (or cosmetic) plastic surgery is a viable […] Insider Monkey ? 2 months ago RCEL +2.06% AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 13, 2024, at 4:00 p.m. Pacific Daylight Time (August 14, 2024, at 9:00 a GlobeNewswire ? 2 months ago AVHHL RCEL +2.06% AVITA Medical Reports Second Quarter Financial Results VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the second quarter ended June 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $15.1 million, an increase of approximately 29% compared to the same period in 2023Gross profit margin of 86.2%RECELL GO? prem GlobeNewswire ? 2 months ago AVHHL RCEL +2.06% AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales VALENCIA, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, is pleased to announce that industry leader Robin VanDenburgh has joined as Senior Vice President of U.S. Commercial Sales, effective August 6, 2024. VanDenburgh, who most recently served as Vice President of Key Accounts at Smith & Nephew (NYSE: SNN), will spearhead AVI GlobeNewswire ? 3 months ago AVHHL RCEL +2.06% SNN AVITA signs dermal matrix distribution agreement with Regenity AVITA will have exclusive marketing, sales, and distribution rights for the dermal matrix in the US. Medical Device Network ? 3 months ago 4735.TWO RCEL +2.06% AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care Exclusive development and distribution agreement with Regenity Biosciences provides AVITA Medical with the commercialization rights to a unique collagen-based dermal matrix following 510(k) clearanceVALENCIA, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has entered into an exclusive multi-year development GlobeNewswire ? 3 months ago AVHHL RCEL +2.06% AVITA Medical to Announce Second Quarter 2024 Financial Results VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Thursday, August 8, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 9, 2024, at 6 GlobeNewswire ? 3 months ago AVHHL RCEL +2.06% AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary Donna Shiroma retires after distinguished service as General CounselVALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal expe GlobeNewswire ? 4 months ago AVHHL RCEL +2.06% Institutions own 46% of AVITA Medical, Inc. (NASDAQ:RCEL) shares but retail investors control 50% of the company Key Insights The considerable ownership by retail investors in AVITA Medical indicates that they collectively have a... Simply Wall St. ? 4 months ago AVHHL RCEL +2.06% AVITA Medical Achieves Milestone with First Case Using RECELL GO Joseph M. Still Burn Center at Doctors Hospital of Augusta first to treat a patient using AVITA Medical’s FDA-Approved RECELL GO System for thermal burn wounds and full-thickness skin defectsVALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hospital of Augu GlobeNewswire ? 4 months ago AVHHL RCEL +2.06% Avita obtains FDA approval for cell harvesting device Recell GO System The system can treat thermal burn wounds and full-thickness skin defects by harnessing the regenerative properties of the skin. Medical Device Network ? 5 months ago RCEL +2.06% AVITA Medical Announces FDA Approval of RECELL GO VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the RECELL GO? System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient’s own skin to tre GlobeNewswire ? 5 months ago AVHHL RCEL +2.06% AVITA Medical Inc (AVHHL) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges ... Despite a challenging quarter, AVITA Medical Inc (AVHHL) reaffirms full-year revenue guidance and progresses on strategic initiatives. GuruFocus.com ? 5 months ago RCEL +2.06% Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return RCEL S&P 500 YTD -16.91% +21.24% 1-Year +6.54% +32.68% 3-Year -41.09% +23.56%
